01051nas a2200277   4500000000100000008004100001260001200042653001900054653002500073653002000098653001300118653001200131653001400143653002100157653004000178100001300218700001200231700001300243700001200256245005400268856006000322300001200382490000700394520035800401022001400759       2022                            d  c03/202210aHansen disease10aMycobacterium leprae10aQcrB inhibitors10aBacteria10aleprosy10atelacebec10aterminal oxidase10aTuberculosis and other mycobacteria1 aLahiri R1 aAdams L1 aThomas S1 aPethe K00aSensitivity of Mycobacterium leprae to Telacebec.  uhttps://wwwnc.cdc.gov/eid/article/28/3/pdfs/21-0394.pdf  a749-7510 v283 a<p>The treatment of leprosy is long and complex, benefiting from the development of sterilizing, rapidly-acting drugs. Reductive evolution made Mycobacterium leprae exquisitely sensitive to Telacebec, a phase 2 drug candidate for tuberculosis The unprecedented potency of Telacebec against M. leprae warrants further validation in clinical trials.</p>
  a1080-6059